Leerink Swann calls the early success of Merck's (MRK +4.2%) odnacatib osteoporosis drug a "positive upside surprise," and forecasts peak sales of $975M in 2020, and a total global sales potential of $3B+. Leerink Swann also maintains its Outperform rating on Merck's stock, while Citigroup ups its rating to "buy" from "neutral."
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Tue, 6:05PM)
at MarketWatch.com (Mon, 11:08AM)
at CNBC.com (Feb 4, 2015)
at MarketWatch.com (Feb 2, 2015)
at Nasdaq.com (Jan 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs